DK1531819T3 - Anvendelse af ikappab kinaseinhibitorer i smertebehandlingen - Google Patents

Anvendelse af ikappab kinaseinhibitorer i smertebehandlingen

Info

Publication number
DK1531819T3
DK1531819T3 DK03753349T DK03753349T DK1531819T3 DK 1531819 T3 DK1531819 T3 DK 1531819T3 DK 03753349 T DK03753349 T DK 03753349T DK 03753349 T DK03753349 T DK 03753349T DK 1531819 T3 DK1531819 T3 DK 1531819T3
Authority
DK
Denmark
Prior art keywords
kinase inhibitors
pain management
ikappab kinase
ikappab
pain
Prior art date
Application number
DK03753349T
Other languages
English (en)
Inventor
Martin Michaelis
Olaf Ritzeler
Gerhard Jaehne
Karl Rudolphi
Gerd Geisslinger
Hans-Georg Schaible
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1531819T3 publication Critical patent/DK1531819T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Paper (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK03753349T 2002-08-17 2003-08-05 Anvendelse af ikappab kinaseinhibitorer i smertebehandlingen DK1531819T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10237723A DE10237723A1 (de) 2002-08-17 2002-08-17 Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
PCT/EP2003/008628 WO2004022057A1 (de) 2002-08-17 2003-08-05 VERWENDUNG VON IκB-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE

Publications (1)

Publication Number Publication Date
DK1531819T3 true DK1531819T3 (da) 2009-04-20

Family

ID=31968975

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03753349T DK1531819T3 (da) 2002-08-17 2003-08-05 Anvendelse af ikappab kinaseinhibitorer i smertebehandlingen

Country Status (34)

Country Link
EP (1) EP1531819B1 (da)
JP (1) JP4504811B2 (da)
KR (2) KR101119845B1 (da)
CN (1) CN100398107C (da)
AR (1) AR043045A1 (da)
AT (1) ATE418336T1 (da)
AU (1) AU2003271555B2 (da)
BR (1) BR0313555A (da)
CA (1) CA2495455C (da)
CO (1) CO5690585A2 (da)
CR (1) CR7716A (da)
CY (1) CY1108874T1 (da)
DE (2) DE10237723A1 (da)
DK (1) DK1531819T3 (da)
EC (1) ECSP055609A (da)
ES (1) ES2320118T3 (da)
HK (1) HK1079426A1 (da)
HR (1) HRP20050041B1 (da)
IL (1) IL166780A (da)
MA (1) MA27334A1 (da)
MX (1) MXPA05001218A (da)
MY (1) MY138059A (da)
NO (1) NO334309B1 (da)
OA (1) OA12907A (da)
PL (1) PL212356B1 (da)
PT (1) PT1531819E (da)
RS (1) RS51878B (da)
RU (1) RU2320338C2 (da)
SI (1) SI1531819T1 (da)
TN (1) TNSN05044A1 (da)
TW (1) TWI325782B (da)
UA (1) UA80837C2 (da)
WO (1) WO2004022057A1 (da)
ZA (1) ZA200500323B (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
BRPI0511834A (pt) 2004-07-14 2008-01-08 Ptc Therapeutics Inc métodos por tratar hepatite c
CN101022802A (zh) 2004-07-22 2007-08-22 Ptc医疗公司 用于治疗丙型肝炎的噻吩并吡啶化合物
DE102005025225A1 (de) 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201242962A (en) * 2010-12-01 2012-11-01 Sumitomo Chemical Co Pyrimidine compound and use for pest control thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ES2612217T3 (es) 2011-12-06 2017-05-12 Sanofi Formas cristalinas de [(S)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida del ácido 2-(2-metilamino-pirimidin-4-il)-1H-indol-5-carboxílico
EP2805705B1 (en) 2013-05-23 2016-11-09 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
JP6553179B2 (ja) * 2014-07-03 2019-07-31 サノフイSanofi 骨関節炎に関連する疼痛の治療で使用するための2−(2−メチルアミノ−ピリミジン−4−イル)−1h−インドール−5−カルボン酸[(s)−1−カルバモイル−2−(フェニル−ピリミジン−2−イル−アミノ)−エチル]−アミド
AU2019304216B2 (en) 2018-07-16 2022-06-02 Novartis Ag Chemical process for preparing phenylpiperidinyl indole derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL206826B1 (pl) * 1999-06-23 2010-09-30 Sanofi Aventis Deutschland Podstawione benzimidazole
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
WO2004022057A1 (de) 2004-03-18
CN100398107C (zh) 2008-07-02
OA12907A (en) 2006-10-13
PL212356B1 (pl) 2012-09-28
CR7716A (es) 2008-11-25
DE10237723A1 (de) 2004-07-08
TWI325782B (en) 2010-06-11
CA2495455A1 (en) 2004-03-18
IL166780A0 (en) 2006-01-15
PT1531819E (pt) 2009-02-18
ZA200500323B (en) 2006-02-22
MXPA05001218A (es) 2005-05-16
PL373568A1 (en) 2005-09-05
CY1108874T1 (el) 2014-07-02
ES2320118T3 (es) 2009-05-19
HRP20050041B1 (hr) 2013-07-31
NO334309B1 (no) 2014-02-03
EP1531819A1 (de) 2005-05-25
CN1674899A (zh) 2005-09-28
RU2005107419A (ru) 2005-08-10
TW200417370A (en) 2004-09-16
SI1531819T1 (sl) 2009-06-30
JP2005539053A (ja) 2005-12-22
DE50310980D1 (de) 2009-02-05
KR101119845B1 (ko) 2012-02-28
IL166780A (en) 2011-11-30
HRP20050041A2 (hr) 2006-04-30
TNSN05044A1 (en) 2007-05-14
BR0313555A (pt) 2005-07-12
KR20050058339A (ko) 2005-06-16
UA80837C2 (uk) 2007-11-12
HK1079426A1 (en) 2006-04-07
KR20110135428A (ko) 2011-12-16
CA2495455C (en) 2011-01-11
NO20051339L (no) 2005-05-03
JP4504811B2 (ja) 2010-07-14
MY138059A (en) 2009-04-30
RS20050070A (en) 2007-06-04
ATE418336T1 (de) 2009-01-15
ECSP055609A (es) 2005-04-18
RS51878B (sr) 2012-02-29
CO5690585A2 (es) 2006-10-31
EP1531819B1 (de) 2008-12-24
RU2320338C2 (ru) 2008-03-27
AU2003271555A1 (en) 2004-03-29
AR043045A1 (es) 2005-07-13
MA27334A1 (fr) 2005-05-02
AU2003271555B2 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
DK1531819T3 (da) Anvendelse af ikappab kinaseinhibitorer i smertebehandlingen
DK1534290T3 (da) Hidtil ukendte kinasehæmmere
IS7700A (is) Ný spíróþétt kínasólínón og notkun þeirra sem fosfórdíesterasa hindrar
DK1532138T3 (da) Inhibitorer af tyrosinkinaser
IS7599A (is) Heterósýklískir kínasatálmar
HK1067945A1 (en) Substituted benzazoles and use thereof as raf kinase inhibitors
DE60313106D1 (de) Zugangsverwaltung
IS6968A (is) Nýir týrósínkínasa tálmar
ES2867378T8 (es) Epinefrina inhalable
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
NO20021341D0 (no) Autentisering og tilgangsstyring
DE50209166D1 (de) Innenkühlbare Schraube
ATE423117T1 (de) Heterocyclische 7-aminoalkylidenylchinolone und - naphthyridone
SE0400663L (sv) Hantering av osäkerhet i ledningssystem
NO20044104L (no) Ikke-nukleoside reverstranskriptase-inhibitorer
DE602004022935D1 (de) Verbesserungen des stimulationserfolgs-managements
ATE373648T1 (de) Nf-kappab-inhibitoren
DE60229669D1 (de) X-2 inhibitoren
DE60316792D1 (de) Pharmazeutische verwendung von cox-2-hemmern in angiogenese-vermittelten augenerkrankungen
SE0203540D0 (sv) Use of an inhibilor or antagonist against lissue factor
SE0200545D0 (sv) Use of an inhibitor or antagonist against tissue factor
DK1529034T3 (da) Benzoylpyrazoloner substitueret med 3-aminocarbonyl
SE0201844D0 (sv) New methods and use
EE05396B1 (et) Peg-seotud proteiinkinaasi inhibiitor ja selle kasutamine
SE0202625D0 (sv) New Composition use and method